Daewoong Pharmaceutical Company Ltd.

The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show

Major South Korean pharma firms have reported mixed earnings for the third quarter ended 30 September, with Yuhan logging strong earnings after the US approval of its novel lung cancer drug and Hanmi

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as othe